Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Item 7.01 indicates Regulation FD disclosure, but the provided text contains only an incorporation-by-reference disclaimer.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Item 7.01 indicates Regulation FD disclosure, but the provided text contains only an incorporation-by-reference disclaimer
- No substantive business, financial, or investor-relevant information appears in the excerpt
Item EX-99.1 · Exhibit EX-99.1
- Corporate presentation outlines Gyre’s China-enabled, capital-efficient pipeline across oncology, autoimmune disease, pain and fibrosis
- ETUARY FY26 revenue guidance of $100.5M-$111M provides commercial funding for early-stage research and development
- F351 Phase 3 met its fibrosis endpoint: 52.85% regression versus 29.84% placebo, with p=0.0002
- F351 NDA accepted for China NMPA review in May 2026, with potential launch in early 2027
- CG001419 Phase 1 showed target engagement at DC50 2.1 ng/mL and DC90 16 ng/mL, supporting planned Phase 2 development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.